


Schizophrenia

Schizophrenia is one of the top 15 leading cause of disability worldwide



Antipsychotics in management of schizophrenia



Long-acting injections (LAIs) in managing schizophrenia

- Guaranteed administration and adherence
- Allows prompt intervention if patients fail to take their medication
- Lesser rebound symptoms
- Lower relapse rates
- Consistent bioavailability
- More predictable correlation between dosage and plasma levels
- Reduced peak-trough plasma levels
- Reduced risk of unintentional or deliberate overdose
- Minimal gastrointestinal absorption problems, circumventing first-pass metabolism
- Improved patient outcomes
- Higher patient and physician satisfaction
- Regular contact between the patient and mental healthcare team

Clinical trials illustrating above advantages are few owing to certain execution difficulties

Challenges in successfully executing clinical trials

- Patient recruitment
- Higher dropout rates
- Study treatment and visit non compliance
- Adherence to protocol and study requirement

How CBCC overcomes these challenges

- Access to huge databases of psychiatry patients
- Largest site network with experience of PK studies
- >50% sites inspected by the FDA
- Advisors/KOLs with >3 decades of experience
- Avoids referrals: PIs are sensitised to enrol patients having long term association with them
- Enrolment of only those patients with caretakers
- Excellent track record of long-term patient follow-up
- Multiple quality checks at each stage of the clinical study
- Fewer drop-out rates for psychiatry trials (<10%)

CBCC is one of the most experienced CRO for conducting Psychiatry LAI trials having worked on molecules like Risperidone, Paliperidone, Olanzapine and Aripiprazole. With this experience, CBCC is committed to aid sponsors in successfully executing psychiatry trials.